KI Innovations AB

This is indeed a great chance to get inspired, get some useful insights and tips from one of our DRIVE alumni champions. For anyone who has been following the marketing and communication efforts from Sigrid Therapeutics, it is easy to see that a lot of time and effort has been put into it. Has it been easy? At what point did random posts become a strategy? Can it be done in-house? And if yes, for how long? What are the biggest advantages?   So many questions that can be asked and answered during this morning while sipping on a coffee and having some breakfast.   Hope to see you there. #innovation #entrepreneur #lifescience #kiinnovations #kisciencepark #awl

Highlight of the week- Catalyzer DRAGONS` DEN. I great pleasure to see the steps the companies in the incubator program have taken during the Catalyzer program. All five companies, Analecto presented by Peter Svensson, Ciprocity presented by Petter Säterskog, Zerocyte Medical AB presented by Josefin Brännström, VoxlBio presented by Hower Lee and NEXUS Epigenomics presented by Mukund Kabbe, PhD had persuasive presentations and we are eager to keep working with them all and seeing how these promising ventures continue to grow and make an impact! We want to extend a big thank you to our esteemed jury Gustav Notander from Almi Invest and Viktor Drvota from Karolinska Development and Teodora Andonova, PhD. If you want to meet our incubator companies and hear them pitch - keep a look out for KI Innovations InvestorDay 2025 coming up April 10th. More information will be out soon both here and on our webpage. See you soon!

We are ready! The finale of the Catalyzer program for all the new DRIVE incubator companies, the DRAGONS’ DEN is about to begin. Good luck Analecto , Ciprocity , Zerocyte Medical AB , VoxlBio and Nexus.

 Another job opportunity from a incubator company from the KI Innovations family. If you’re passionate about driving innovation and working towards impact with cutting-edge technologies, this could be just the position for you! Good luck,

More great news from the KI Innovations alumni portfolio! Gesynta Pharma AB raises SEK 304 million to Advance Novel Endometriosis Treatment. In a press release from today, January 20, 2025, Gesynta Pharma AB announces that it has secured SEK 304 million in a Series B financing round, securing investments from existing and new investors such as Hadean Ventures, Industrifonden, Linc, Foreground Capital, Catalyze Capital, Stephen Industries and Amboy Street Venturesthat, demonstrating strong international investor confidence in Gesyntas approach to treating endometriosis. "With these funds, we will advance vipoglanstat towards being Phase III-ready, aiming to provide patients with a disease-modifying treatment option that overcomes the efficacy and tolerability limitations of current therapies,” says Patric Stenberg, CEO of Gesynta Pharma. Endometriosis, a painful chronic inflammatory disease, significantly impairs the health and quality of life for over 10% of women of reproductive age. Congratulations to Patric Stenberg and team Gesynta! Full press release here: https://www.gesynta.se/ #innovation #lifescience #entrepreneur #impact

Such a strong start to 2025 for KI Innovations incubator companies and almunies. We are very happy to share the excellent news from last week, and congratualte AnaCardio, Lars Lund, Patrik Strömberg and team to secure USD 19 million to advance AC01 development for heart failure and reports positive result from Phase 1b study. Read more about this exciting milestone and their Phase 1b results here: https://lnkd.in/dwKp2XXH. Congrats!

Super interesting news - A new international study by researchers at Karolinska Institutet led by Elisabeth Epstein, founder of KI Innovations Incubator company Intelligyn shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images. The study is published in Nature Medicine. There is a serious shortage of ultrasound experts in many parts of the world, which has raised concerns of unnecessary interventions and delayed cancer diagnoses. Intelligyn offers ultrasound images during the ultrasound scan and provides instant risk predictions for ovarian tumors and management suggestions. Read the news on KIs web page, https://lnkd.in/dh5_BCF9.

A heartfelt thank you to all partners, coaches, owners, innovation support systems, investors, and enablers who have helped us make Sweden a hub for competitive, sustainable innovations! This year, we’ve worked together to: 🌟 Rethink and refine ideas to unlock their true potential. 🌟 Build strong teams and attract investments. 🌟 Develop groundbreaking services and products. 🌟 Explore new markets and connect with customers. We look forward to 2025 filled with new startups and more scaleups and their bold innovations, and new opportunities to connect, inspire, and celebrate success! Before we go into a new year we want to inform you about an exciting date for next year. 💲 KI Innovations InvestorDay 2025| 10 april 2025 – Meet Startups, investors and stakeholders on a mission to impact society. See you in 2025! https://lnkd.in/d_jW5Pxw

Tack KI Science Park Lunch Talks för ett intressant samtal kring temat - Vilka möjligheter ger teknikutvecklingen idag och vad krävs för att alla patienter och hela hälso- och sjukvården ska få ta del av banbrytande innovation? Väldigt intressant att höra från en kunnig panel med olika synvinklar men med samma intresse för hur vi gemensamt skall kunna implementera nya innovationer i sjukvården nationellt. Frågorna som diskuterades var: ✅️ Hur ser nuläget ut, vilka nya möjligheter står till förfogande och vad krävs för att patienter och hälso-och sjukvård ska ges tillgång till dessa nyheter? ✅️Hur kan vi tillsammans utveckla hälso- och sjukvården samtidigt som ordinarie vård hinns med och kan finansieras? Vi fick höra en lite längre utläggning från Nasim Bergman Farrokhnia, Microsoft och Ann Lindgård, Siish/VGR som även deltog i panelen tillsammans med Daniel Forslund Vårdföretagarna, Nina Lahti, AI Sweden, Carl-Johan Schiller, regionråd (KD) Region Stockholm. Moderator var som alltid lika duktiga Edvard Agrell från Bayer. Tack. Det var mycket att ta med sig från detta lunchsamtal, men i korthet och ganska beskrivande kan jag summera med: 1 ) Möjliggör - det finns inte oändligt med tid och tid krävs så detta måste in i system att tillsätta tid för att möjliggöra kreativt innovatiosarbete. 2) Släck inte gnistan - När man känner att man kan förändra, att det finns utrymme för det så vill man försöka. Många nej inte nu eller ännu värre, inga svar släcker gnistan. 3) Krävs mod för att våga testa. Tack för årets lunch Talks KI Science Park, Bayer och Waters Corporation

Earlier this week, we had the pleasure of visiting Campus Flemingsberg for an open coaching session, meeting researchers and students with innovative ideas within life science. It’s always inspiring to hear new ideas and discuss the key questions that often come up at this early stage: 🔹 Intellectual Property (IP). How should we think around this?: It’s crucial to address IP early. Publishing before securing a patent can limit future possibilities, so make sure you have a plan in advance.  🔹 Professor’s Privilege – Whay does it mean?: A unique opportunity in Sweden—researchers own their inventions. This creates great potential for innovation, but puts high demands on entrepreneurial skills.  🔹 How can KI Innovations support you? The best way to find out is to visit our website https://lnkd.in/gSE_SYn or schedule a meeting with one of our business coaches. We’re here to help!   Let’s keep the creativity and drive within our academic community moving forward! 🚀